Ampersand Capital Partners Acquires Biologos

Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announces the acquisition of Biologos LLC (“Biologos”), a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. The partnership with Ampersand will include investments to expand Biologos’ capabilities, product offerings, and geographic reach to support its cell and gene therapy, biopharmaceutical, tissue processing, and animal health customers globally. Founded in 1976, Biologos has become an industry leader providing custom and standard products spanning cell culture media, reagents, enzymes, salts/buffers, and sera, many with customized container, fill, and packaging solutions.

Read the full article: Ampersand Capital Partners Acquires Biologos //


Leave a Comment

Your email address will not be published.

Scroll to Top